Could a new drug combo boost transplant success in lymphoma?

NCT ID NCT01241734

Completed Disease control Sponsor: Hackensack Meridian Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested adding lenalidomide (Revlimid) to standard chemotherapy (RICE) for people with relapsed diffuse large B-cell lymphoma. The goal was to see if the combination is safe and can improve response rates, helping more patients qualify for a stem cell transplant. Only 18 people took part, and the results are early and limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lenalidomide (Revlimid) combined with rituximab, ifosfamide, etoposide, and carboplatin (RICE chemotherapy)
What this could lead to: If this combination works well, it could help more patients with relapsed DLBCL achieve remission and successfully undergo a stem cell transplant, potentially improving long-term survival.
What could go wrong: This is a small, early-phase trial (18 participants) testing safety and dosing, not a proven treatment. The added lenalidomide may increase side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

Duke University Medical Center

Durham, North Carolina, 27710, United States
John Theurer Cancer Center at Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.